Investors

Corporate Profile
We are a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases.

Leveraging our proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, we have developed a pipeline of product candidates targeting markets with high unmet medical needs. Our initial focus is on the treatment of blood cancers, including acute lymphoblastic leukemia, or ALL, and acute myeloid leukemia, or AML, by depriving tumors of nutrients necessary for their survival, which is referred to as tumor starvation.
Stock Quote
ExchangeParis (Euro)
Price€16.45
Change (%) Stock is Down 0.18 (1.08%)
Volume14,162
Data as of 05/25/18 5:35 p.m. ET
Refresh quote
Recent NewsMore >>
DateTitle  
14-May-2018ERYTECH Reports First Quarter 2018 Financial Results and Provides Business Update
Conference call and webcast scheduled for Tuesday, May 15th at 2:30 pm CET/8:30 am EDT Finalized Phase 3 trial design for eryaspase in second line pancreatic cancer; on track for expected start of patient enrollment in Q3 Selected triple-negative breast cancer as the next solid tumor indication; preparing Phase 2 trial with expected start of patient enrollment in Q3 Reported pos... 
 Printer Friendly Version
14-May-2018ERYTECH Strengthens Executive Team with the Appointment of Alex Dusek as VP of Commercial Strategy
LYON, France--(BUSINESS WIRE)--May 14, 2018-- Regulatory News: ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announced that it has appointed Alex Dusek as its Vice President Commercial Strategy and member of the executive team. Mr. Dusek brings 25 years of experience in market access, product mar... 
 Printer Friendly Version
09-May-2018ERYTECH to Host First Quarter 2018 Conference Call and Business Update
LYON, France--(BUSINESS WIRE)--May 9, 2018-- Regulatory News: ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host its 2018 first quarter conference call and webcast on Tuesday, May 15, 2018, at 2:30 PM CEST/8:30 AM EST to discuss operational highlights. ... 
 Printer Friendly Version
03-May-2018Erytech: Monthly Information Related to Total Number of Voting Rights and Shares Composing the Share Capital – April 30, 2018
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France--(BUSINESS WIRE)--May 3, 2018-- Regulatory News: Erytech (Euronext: ERYP- Nasdaq: ERYP): Listing markets: Euronext Paris from Euronext (Market segment B - ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States (Symbol : ERYP) Website : www.erytech.com Date ... 
 Printer Friendly Version
Upcoming EventsMore >>
DateTitle
06/28/18 10:00 a.m. CET
General Meeting of Shareholders
LocationLyon
09/18/18 2:30 p.m. CET
Erytech Pharma Second Quarter 2018 Conference Call and Webcast
11/13/18 2:30 p.m. CET
Erytech Pharma Third Quarter 2018 Conference Call and Webcast
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Erytech Pharma SA posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources